Chemistry:Epristeride
 | |
| Clinical data | |
|---|---|
| Trade names | Aipuliete, Chuanliu |
| Other names | ONO-9302; SKF-105657; 17β-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid |
| Routes of administration | By mouth[1] |
| Drug class | 5α-Reductase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 93%[2] |
| Elimination half-life | 26 hours[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H37NO3 |
| Molar mass | 399.575 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Epristeride, sold under the brand names Aipuliete and Chuanliu, is a medication which is used in the treatment of enlarged prostate in China .[3][4][5] It is taken by mouth.[1]
Epristeride is a 5α-reductase inhibitor and works by decreasing the production of dihydrotestosterone (DHT), an androgen sex hormone, in certain parts of the body like the prostate gland.[6][7][8] It inhibits two of the three forms of 5α-reductase but is of relatively low efficacy and can decrease DHT levels in the blood only by about 25 to 54%.[8]
Epristeride was under development for the treatment of enlarged prostate, scalp hair loss, and acne in the United States and other countries in the 1990s but did not complete development in these countries.[6][4] Instead, it was developed and introduced for the treatment of enlarged prostate in China in 2000.[4]
Medical uses
Epristeride is used in the treatment of benign prostatic hyperplasia (BPH), otherwise known as enlarged prostate.[3][4]
Pharmacology
Pharmacodynamics
Epristeride is a selective, transition-state, non-competitive or uncompetitive, irreversible inhibitor of 5α-reductase,[6][7] and is specific to the type II isoform of the enzyme similarly to finasteride and turosteride but unlike dutasteride.[8]
Epristeride is unique in its mechanism of action relative to finasteride and dutasteride in that it binds irreversibly to 5α-reductase and results in the formation of an unproductive complex of the 5α-reductase enzyme, the substrate testosterone, and the cofactor NADPH.[8][9] For this reason, testosterone is caught in a trap, and it was initially speculated that the reciprocal increase in intraprostatic levels of testosterone seen with finasteride and dutasteride should not happen with epristeride.[8][9] However, subsequent clinical data have not supported this hypothesis.[8] Moreover, in spite of the fact that epristeride is a very potent inhibitor of 5α-reductase type II (0.18–2 nM), it has been found to reduce circulating levels of dihydrotestosterone (DHT) by only 25 to 54% following 8 days of therapy over a dosage range of 0.4 to 160 mg/day.[8] For this reason, relative to other 5α-reductase inhibitors like finasteride and dutasteride, the degree of DHT suppression with epristeride falls short of that desirable for full clinical benefit.[8]
Pharmacokinetics
The oral bioavailability of epristeride is 93%.[2] It has an elimination half-life of 26 hours.[2]
Chemistry
Epristeride, also known as 17β-(tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid, is a synthetic androstane steroid.
History
Epristeride was under development for the treatment of BPH, androgenic alopecia (pattern hair loss), and acne vulgaris by SmithKline Beecham (now GlaxoSmithKline) in the 1990s and reached phase III clinical trials in the United States , United Kingdom , and Japan ,[6] but ultimately was never marketed in these countries.[4] Instead, epristeride was developed by Ono Pharmaceutical and introduced for the treatment of BPH in China in 2000.[4]
Society and culture
Generic names
Epristeride is the generic name of the drug and its INN, USAN, BAN, and JAN.[5]
Brand names
Epristeride is marketed under the brand names Aipuliete and Chuanliu in China.[5][4]
References
- ↑ 1.0 1.1 "Enzymes and enzyme inhibitors". Textbook of Drug Design and Discovery (Third ed.). CRC Press. 2 August 2003. pp. 400–. ISBN 978-0-203-30137-1. https://books.google.com/books?id=ZjzdazsyRVoC&pg=PA400.
- ↑ 2.0 2.1 2.2 2.3 "Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects". Biopharmaceutics & Drug Disposition 17 (3): 249–258. April 1996. doi:10.1002/(SICI)1099-081X(199604)17:3<249::AID-BDD952>3.0.CO;2-E. PMID 8983399.
- ↑ 3.0 3.1 Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 31 October 1999. pp. 113–. ISBN 978-0-7514-0499-9. https://books.google.com/books?id=mqaOMOtk61IC&pg=PA113.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 "Epristeride". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800002533.
- ↑ 5.0 5.1 5.2 "List of 21 Benign Prostatic Hyperplasia Medications Compared". Drugs.com. https://www.drugs.com/international/epristeride.html.
- ↑ 6.0 6.1 6.2 6.3 "Epristeride SmithKline Beecham". IDrugs 1 (1): 152–157. May 1998. PMID 18465521.
- ↑ 7.0 7.1 "Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture". The Prostate 32 (3): 155–163. August 1997. doi:10.1002/(SICI)1097-0045(19970801)32:3<155::AID-PROS1>3.0.CO;2-K. PMID 9254894.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 "Inhibitors of 5 alpha-Reductase". Current Pharmaceutical Design (Bentham Science Publishers) 2 (1): 70–. February 1996. https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA70.
- ↑ 9.0 9.1 "Anti-hormome Therapy: Principles of Endocrine Therapy of Cancer". Cancer. Springer Science & Business Media. 30 January 2007. pp. 49–. ISBN 978-3-540-33120-9. https://books.google.com/books?id=fdtDAAAAQBAJ&pg=PA49.
External links
{{Navbox
| name = Drugs used in benign prostatic hypertrophy | title = Drugs used in [[Medicine:Benign prostatic hyperpbenign prostatic hyperplasia (G04C) | state = collapsed | listclass = hlist
| group1 = 5α-Reductase inhibitors | list1 =
| group2 = Alpha-1 blockers | list2 =
| group3 = Steroidal antiandrogens | list3 =
| group4 = Herbal products | list4 =
| group5 = Others | list5 =
}} {{Navbox
| name = Androgens and antiandrogens | title = Androgens and antiandrogens | state = collapsed | listclass = hlist | groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)
| list1 =
| group2 = Antiandrogens | list2 = {{Navbox|child | groupstyle = text-align:center; | groupwidth = 9em;
| group1 = AR antagonists | list1 =
- Steroidal: Abiraterone acetate
- Canrenone
- Chlormadinone acetate
- Cyproterone acetate
- Delmadinone acetate
- Dienogest
- Drospirenone
- Medrogestone
- Megestrol acetate
- Nomegestrol acetate
- Osaterone acetate
- Oxendolone
- Potassium canrenoate
- Spironolactone
- Nonsteroidal: Apalutamide
- Bicalutamide
- Cimetidine
- Darolutamide
- Enzalutamide
- Flutamide
- Ketoconazole
- Nilutamide
- Seviteronel†
- Topilutamide (fluridil)
| group2 = Steroidogenesis| list2 =
inhibitors
| 5α-Reductase | |
|---|---|
| Others |
| group3 = Antigonadotropins | list3 =
- D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
- Estrogens (e.g., bifluranol, [[diethylstilbestrol, estradiol, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)
- GnRH agonists (e.g., leuprorelin)
- GnRH antagonists (e.g., cetrorelix)
- Progestogens (incl., chlormadinone acetate, [[cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, [[Chemistry:Medroxyprogesterone medroxyprogesterone acetate, Chemistry:Megestrol acetate|megestrol acetate]])
| group4 = Others | list4 =
- Androstenedione immunogens: Androvax (androstenedione albumin)
- Ovandrotone albumin (Fecundin)
}}
| liststyle = background:#DDDDFF;| list3 =
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Androgen receptor modulators
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
- List of androgens/anabolic steroids
}}
 |  |
